Novavax (NVAX) is reshaping its business model after handing European commercialization of its COVID-19 vaccine to Sanofi and prioritizing partnerships that license out its Matrix-M adjuvant technology.

Recent stock moves reflect that shift in focus. Despite a 1-day share price return of 5.49% to US$9.03, the 7-day and 90-day share price returns are down 11.38% and 11.77%. The year-to-date share price return of 26.65% sits alongside a 1-year total shareholder return of 26.29% and a 5-year total shareholder return that is down 94.98%, suggesting that recent momentum is improving from a much weaker long-term base.

If you are weighing Novavax against other opportunities in healthcare, this is a good moment to size up 40 healthcare AI stocks.

With the stock up year to date but still far below its 5 year level and trading at a discount to analyst price targets and some intrinsic value estimates, is Novavax undervalued today, or is the market already pricing in future growth?

Most Popular Narrative: 34.5% Undervalued

With Novavax last closing at $9.03 against a narrative fair value of $13.78, the popular view in the market community leans toward a sizeable valuation gap driven by its licensing shift.

The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.

Want to see what sits behind that valuation gap? The narrative leans heavily on future margins, shrinking top line expectations, and a premium earnings multiple tied to those forecasts.

Result: Fair Value of $13.78 (UNDERVALUED)

However, this hinges on partners like Sanofi and Pfizer hitting regulatory and commercial milestones, and on COVID vaccine demand not fading more quickly than analysts currently model.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given that the story here is mixed, with both concerns and reasons for optimism, it may be worth acting promptly and reviewing the numbers yourself using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Novavax has caught your eye, do not stop here. Broaden your watchlist with other focused opportunities that could sharpen your overall portfolio.

• Target resilience first by scanning companies flagged as 67 resilient stocks with low risk scores before market sentiment shifts again.
• Seek value by reviewing companies identified in the 46 high quality undervalued stocks that combine solid fundamentals with attractive pricing.
• Spot earlier opportunities by checking the screener containing 20 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.